

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-98)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Collection of information unless it contains a valid OMB control number.

Substitutes for form 1448A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/088,250
				Filing Date	December 23, 2002
				First Named Inventor	FINK, et al.
				Group Art Unit	1626
				Examiner Name	SHAMEEM, Golam M
				Attorney Docket Number	USHMR2023 - US - PCT
Sheet	1	of	2		

[illegible][illegible]

Examiner Signature	<i>A. Hameem</i>	Date Considered	<i>1/26/06</i>
-----------------------	------------------	--------------------	----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

NOV. 29. 2005 2:03PM AVENTIS US PAT DEPT

NO. 0075 P. 7

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-95)  
Approved for use through 10/31/99. OMB 0551-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/088,250
				Filing Date	December 23, 2002
				First Named Inventor	FINK, et al.
				Group Art Unit	1626
				Examiner Name	SHAMEEM, Golam M
				Attorney Docket Number	USHMR2023 - US - PCT
Sheet	2	of	2		

[illegible]

Examiner Signature	<i>LS</i>	Date Considered	1/24/06
-----------------------	-----------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

PAGE 7/22 \* RCVD AT 11/29/2005 1:49:32 PM (Eastern Standard Time) \* SVR:USPTO-EFXXF-6/33 \* DNIS:2738300 \* CSID:908 231 2626 \* DURATION (mm:ss):05:42

\* missing reference - has not been considered.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08A (10-95)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/088,250
		Filing Date	12-23-2002
		First Named Inventor	FINK, et. al.
		Group Art Unit	1626
		Examiner Name	SHAMEEM, Golam M.
Sheet 1 of 5	Attorney Docket Number	USHMR2023 - US - PCT	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
29	*	4,075,227		JONES, et. al.	02-21-1978	
	*	4,085,114		ADACHI, et. al.	04-18-1978	
	*	4,355,037		STRUPCZEWSKI, et. al.	10-19-1982	
	*	4,408,053		STRUPCZEWSKI, et. al.	10-04-1983	
	*	4,408,054		STRUPCZEWSKI, et. al.	10-04-1983	
	*	4,427,891		SHUTSKE, et. al.	01-24-1984	
	*	4,452,804		SHUTSKE, et. al.	06-06-1984	
	*	4,469,869		STRUPCZEWSKI, et. al.	09-04-1984	
	*	4,504,669		SHUTSKE, et. al.	03-12-1985	
	*	4,528,376		STRUPCZEWSKI, et. al.	07-09-1985	
	*	4,644,064		SHUTSKE, et. al.	02-17-1987	
	*	4,728,651		ONG, et. al.	03-01-1988	
	*	4,769,472		ONG, et. al.	09-06-1988	
	*	5,254,595		GUZZI, et. al.	10-19-1993	
	*	5,321,037		NAGANO, et. al.	06-14-1994	
	*	5,340,833		BRIDGES, et. al.	08-23-1994	
	*	5,593,994		BATT, et. al.	01-14-1997	
	*	5,696,113		PALERMO, et. al.	12-09-1997	
28	*	5,843,940		CULLINAN, et. al.	12-01-1998	
	*	5,856,503		AEBI, et. al.	01-05-1999	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
29	*	EP	0058977		SHUTSKE, et. al.	09-01-1982	
	*	EP	0221414		ONG, et. al.	05-13-1987	
	*	EP	0729955		CULLINAN, et. al.	09-04-1996	
	*	WO	01/19833		FINK, et. al.	03-22-2001	
	*	WO	97/28115		ADAMS, et. al.	08-07-1997	
28	*	GB	1,269,776		SMITH, et. al.	04-06-1972	

Examiner Signature	<i>Shameem</i>	Date Considered	1/26/06
--------------------	----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	10/088,250
				Filing Date	12-23-2002
				First Named Inventor	FINK, et. al.
				Group Art Unit	1626
				Examiner Name	SHAMEEM, Golam M.
Sheet	2	of	5	Attorney Docket Number	USHMR2023 - US - PCT

[illegible][illegible]

**Examiner  
Signature**

*Chen*

Date Considered

1126106


<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

### Complete if Known

Application Number	10/088,250
Filing Date	12-23-2002
First Named Inventor	FINK, et. al.
Group Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	USHMR2023 - US - PCT

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	*	ASGHARI, V., et al., <u>Dopamine D4 Receptor Repeat: Analysis of Different Native and Mutant Forms of the Human and Rat Genes</u> , Molecular Pharmacology Vol. 46, pp. 364-373 (1994)	
	*	BASSITT, D.P., et. al., <u>Clozapine Efficacy in Tardive Dyskinesia in Schizophrenic Patients</u> , European Archives of Psychiatry and Clinical Neuroscience Vol. 248, pp. 209-211 (1998)	
	*	BENJAMIN, J., et. al., <u>Population and Familial Association between the D4 Dopamine Receptor gene and Measures of Novelty Seeking</u> , Nature Genetics Vol. 12, pp. 81-84 (1996)	
	*	BRYCE, M., et. al., <u>Synthesis and Cyclic Voltammetric Behaviour of Some 3-Substituted Thiophenes and Pyrrole: Precursors for the Preparation of Conducting Polymers</u> , Synthetic Metal, Vol. 26, (1988) pp. 153-168	
	*	CORBETT, R., et. al., <u>lloperidone: Preclinical Profile and Early Clinical Evaluation</u> , CNS Drug Review Vol. 3, No. 2, pp. 120-147 (1997)	
	*	CRENSHAW, R.R., et. al., <u>Potential Antifertility Agents. 1. Substituted Diaryl Derivatives of Benzo[b]thiophenes, Benzo[b]furans, 1H-2-Benzothiazopyrans, and 2H-1-Benzothiazopyrans</u> , Journal of Medicinal Chemistry, Vol. 14, No. 12, (1971) pp. 1185-1190	
	*	CRUZ, C., et al., <u>Increased Prevalence of the Seven-Repeat Variant of the Dopamine D4 Receptor Gene in Patients with Obsessive-Compulsive Disorder with Tics</u> , Neuroscience Letters Vol. 231, pp. 1-4, (1997)	
	*	EBSTEIN, R.E., et. al., <u>Dopamine D4 Receptor (D4DR) exon III Polymorphism Associated with the Human Personality Trait of Novelty Seeking</u> , Nature Genetics Vol. 12, (1996) pp. 78-80	
	*	ELWORTHY, T. R., et. al., <u>N-Arylpiperazinyl-N-Propylamino Derivatives of Heteroaryl Amides as Functional Unselective <math>\alpha_1</math>-Adrenoceptor Antagonists</u> , Indian Journal of Chemistry - part B Organic Including Medicinal Vol. 40, pp. 2674-2687, (1997)	
	*	ERENBERG, G., et al., <u>Gilles De La Tourette's Syndrome: Effects of Stimulant Drugs</u> , Neurology Vol. 35, No. 35, pp. 1346-1348, (1985)	

Examiner  
Signature

ES

Date  
Considered

1/28/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

note: References are not in file

Release type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

### Complete if Known

Application Number	10/088,250
Filing Date	12-23-2002
First Named Inventor	FINK, et. al.
Group Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	USHMR2023 - US - PCT

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	*	FACTOR, S.A., et. al., <u>The Emerging Role of Clozapine in the Treatment of Movement Disorders, Movement Disorders Vol. 12, No.4 (1997) pp. 483-496</u>	
	*	FELDPAUSCH, D.L., et. al., <u>The Role of Dopamine D4 Receptor in the Induction of Behavioral Sensitization to Amphetamine and Accompanying Biochemical and Molecular Adaptations, Journal of Pharmacology and Experimental Therapeutics Vol. 266, pp.497-508 (1998)</u>	
	*	FRIEDMAN, J.H., et. al., <u>Substituting Clozapine for Olanzapine in Psychiatrically Stable Parkinson's Disease Patients: Results of an Open Label for Pilot Study, Clinical Neuropharmacology, Vol. 21, No. 5 pp. 285-288 (1998)</u>	
	*	GRICE, D.E., et. al., <u>Linkage Disequilibrium between an Allele at the Dopamine D4 Receptor Locus and Tourette Syndrome, by the Transmission Disequilibrium Test, American Journal of Human Genetics Vol.59, pp.644-652 (1996)</u>	
	*	HELSLEY, G.C., et. al., <u>Piperidylalkylindoles. 1. Hypotensive Activity of 3-[2-(Phenoxypiperidyl)ethyl]Indoles, Journal of Medicinal Chemistry, (1978), Vol.21, No.3 pp. 309-312</u>	
	*	LAHOSTE, G., et. al., <u>Dopamine D4 Receptor Gene Polymorphism is Associated with Attention Deficit Hyperactivity Disorder, Molecular Psychiatry Vol. 1, pp. 121-124 (1996)</u>	
	*	LAHTI, R.A., et. al., <u>Direct Determination of Dopamine D4 Receptors in Normal and Schizophrenic Postmortem Brain Tissue: A [3H]MGO-94-1 Study, Molecular Psychiatry Vol. 3, pp. 528-533 (1998)</u>	
	*	MAGDO, I., et. al., <u>3D quantitative structure-activity relationship (CoMFA) study of heterocyclic arylpiperazine derivatives with 5-HT1A activity, Database Chemabs 'Online' Chemical Abstracts Service, Columbus, Ohio, US</u>	
	*	RICKETTS, H., et. al., <u>Association of Long Variants of the Dopamine D4 Receptor Exon 3 Repeat Polymorphism with Parkinson's Disease, Clinical Genetics Vol. 54, pp. 89-98 (1998)</u>	
	*	RUBINSTEIN, M., et. al., <u>Mice Lacking Dopamine D4 Receptors are Supersensitive to Ethanol, Cocaine, and Methamphetamine, Cell, Vol.90, pp. 991-1001 (1997)</u>	

Examiner Signature		Date Considered	1/28/06
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Note: Not in file

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

### Complete if Known

Application Number	10/088,250
Filing Date	12-23-2002
First Named Inventor	FINK, et. al.
Group Art Unit	1626
Examiner Name	SHAMEEM, Golam M.
Attorney Docket Number	USHMR2023 - US - PCT

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	*	SALL, D., et. al., <del>Dibasic Benzo[b]thiophene Derivatives as a Novel Class of Active Site-Directed Thrombin Inhibitors. 1. Determination of the Serine Protease Selectivity, Structure - Activity Relationships, and Binding Orientation, Journal of Medicinal Chemistry Vol.40, No. 22, (1997) pp. 3489 - 3493</del>	
	*	SCHODER, J.; et. al., <del>D2 Dopamine Receptor Up-Regulation, Treatment Response, Neurological Soft Signs, and Extrapyramidal Side Effects in Schizophrenia: A Follow-Up Study with 123I-Iodobenzamide Single Photon Emission Computed Tomography in the Drug Naive State and after Neuroleptic Treatment, Society of Biological Psychiatry Vol.43, pp.660-665, (1998)</del>	
	*	SEEMAN, P., et. al., <del>Atypical Neuroleptics Have Low Affinity for Dopamine D2 Receptors or Are Selective for D4 Receptors, Neuropsychopharmacology Vol.16, Iss. 2, pp. 92-135 (1997)</del>	
	*	SEEMAN, P., et. al., <del>Schizophrenia: Elevation of dopamine D4-like sites, using [3H]Nemonapride and [125I]Epidepride, European Journal of Pharmacology Vol.286 (1995) R3-R5</del>	
	*	SHIELDS, P.G., et. al., <del>Dopamine D4 Receptors and the Risk of Cigarette Smoke in African-Americans and Caucasians<sup>1</sup>, Cancer Epidemiology, Biomarkers &amp; Prevention Vol. 7, pp.453-458 (1998)</del>	
	*	VAN TOL, H.M., et. al., <del>Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine, Letters to Nature, Vol. 350, 1991, pp 610-614</del>	
	*	VAN TOL, H.M., et. al., <del>The Dopamine D4 Receptor: A Novel Site for Antipsychotic Action, Clinical Neuropharmacology Vol. 18, No 1 pp. 5143-5153 (1995)</del>	
	*	VANTOL, H.M., et. al., <del>Multiple Dopamine D4 Receptor Variants in the Human Population, Nature Vol. 358 - 9 (1992) - pp.149 - 152</del>	
	*	ZHU, J., et. al., <del>Synthesis of 2-(4-Halogenobenzyl)-3-Arylbenzo[b]-Thiophenes and a 2-(4-Fluorobenzyl)-3-Arylbenzo[b]-Selenophene as Selective Ligands for Antiestrogen-Binding Sites</del>	

Examiner  
Signature

*CS*

Date  
Considered

*1/28/06*

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Note: Not in file